Cargando…

Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone

Detalles Bibliográficos
Autores principales:	Chiu, Nicholas, Aggarwal, Rahul, Bakris, George L., Pitt, Bertram, Bhatt, Deepak L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075441/ https://www.ncbi.nlm.nih.gov/pubmed/35311349 http://dx.doi.org/10.1161/JAHA.121.025079

Ejemplares similares

Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials
por: Flack, John M., et al.
Publicado: (2023)

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
por: Ruilope, Luis M, et al.
Publicado: (2022)

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
por: Filippatos, Gerasimos, et al.
Publicado: (2021)

Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2021)

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
por: Rossing, Peter, et al.
Publicado: (2021)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA(1c) and Insulin Use: An Analysis From the FIDELIO-DKD Study
por: Rossing, Peter, et al.
Publicado: (2022)

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2022)

Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis
por: van den Berg, Paul, et al.
Publicado: (2021)

Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk
por: Scilletta, Sabrina, et al.
Publicado: (2023)

Detection of DKD stage 1 and treatment are essential
por: Futrakul, Narisa, et al.
Publicado: (2018)

Role of Sphingolipid Signaling in Glomerular Diseases: Focus on DKD and FSGS
por: Mitrofanova, Alla, et al.
Publicado: (2020)

The role of lncRNAs in regulation of DKD and diabetes-related cancer
por: Cheng, Yawei, et al.
Publicado: (2022)

2DKD: a toolkit for content-based local image search
por: DeVille, Julian S., et al.
Publicado: (2020)

Virtual Patient Simulation in DKD: Successful Strategy for Improving Recognition and Management
por: Larkin, Amy, et al.
Publicado: (2021)

Network Pharmacology-Based Prediction of Mechanism of Shenzhuo Formula for Application to DKD
por: Wang, Xinmiao, et al.
Publicado: (2021)

Lessons learned from two randomized controlled trials: CITIES and STOP-DKD
por: Zullig, Leah L., et al.
Publicado: (2020)

The FIDELIO Study Podcast
por: Toto, Robert, et al.
Publicado: (2022)

ODP223 Metabolic efficacy of Very Low Carbohydrate Diet in DKD patients
por: Zainordin, Nur Aisyah, et al.
Publicado: (2022)

Both sexes develop DKD in the CD1 uninephrectomized streptozotocin mouse model
por: Trink, Jackie, et al.
Publicado: (2023)

Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
por: Willis, Michael, et al.
Publicado: (2020)

The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD
por: de Sá, João Roberto, et al.
Publicado: (2022)

Correction to: The FIDELIO Study Podcast
por: Toto, Robert, et al.
Publicado: (2022)

The Saudi Diabetic Kidney Disease study (Saudi-DKD): clinical characteristics and biochemical parameters
por: Al-Rubeaan, Khalid, et al.
Publicado: (2018)

Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD)
por: Bae, Jaehyun, et al.
Publicado: (2021)

Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
por: Chiu, Nicholas, et al.
Publicado: (2022)

Effects of liraglutide on extraglycemic inflammatory markers and renal hemodynamic parameters in diabetic kidney disease (DKD)
por: Song, Wenjuan, et al.
Publicado: (2023)

Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives
por: Tanase, Daniela Maria, et al.
Publicado: (2022)

A qualitative study documenting unmet needs in the management of diabetic kidney disease (DKD) in the primary care setting
por: Datar, Manasi, et al.
Publicado: (2021)

Fidelio /
por: Beethoven, Ludwig van, 1770-1827
Publicado: (1985)

The harmful intestinal microbial community accumulates during DKD exacerbation and microbiome–metabolome combined validation in a mouse model
por: Shang, Jin, et al.
Publicado: (2022)

Identification of a New RNA and Protein Integrated Biomarker Panel Associated with Kidney Function Impairment in DKD: Translational Implications
por: Scamporrino, Alessandra, et al.
Publicado: (2023)

Fidelio Ponce
por: Sánchez, Juan
Publicado: (1985)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Figaro illustré.
Publicado: (1908)

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
por: Ruilope, Luis M., et al.
Publicado: (2022)

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ci37n6409s0k1avh3pbjh283m2